Your browser doesn't support javascript.
loading
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.
Harding, James J; Garrido-Laguna, Ignacio; Chen, Xiaoying; Basu, Cynthia; Dowlati, Afshin; Forgie, Alison; Hooper, Andrea T; Kamperschroer, Cris; Max, Steven I; Moreau, Allison; Shannon, Megan; Wong, Gilbert Y; Hong, David S.
Affiliation
  • Harding JJ; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States.
  • Garrido-Laguna I; Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, United States.
  • Chen X; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Basu C; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Dowlati A; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, United States.
  • Forgie A; Early Clinical Development and Oncology Research, Worldwide Research and Development, Pfizer, San Francisco, CA, United States.
  • Hooper AT; Oncology Research and Development, Pfizer, Inc., Pearl River, NY, United States.
  • Kamperschroer C; Drug Safety Research and Development, Worldwide Research and Development, Pfizer, Groton, CT, United States.
  • Max SI; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Moreau A; Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, PA, United States.
  • Shannon M; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Wong GY; Early Oncology Development and Clinical Research, Worldwide Research and Development, Pfizer, San Diego, CA, United States.
  • Hong DS; Early Clinical Development and Oncology Research, Worldwide Research and Development, Pfizer, San Francisco, CA, United States.
Front Immunol ; 13: 845417, 2022.
Article in En | MEDLINE | ID: mdl-35493516
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Bispecific / Neoplasms Limits: Adult / Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: United States Country of publication: Switzerland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Bispecific / Neoplasms Limits: Adult / Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: United States Country of publication: Switzerland